Laser Ablation of Papillary Thyroid Microcarcinoma

Sponsor: Memorial Sloan Kettering Cancer Center

Sponsor score: 60
Inactive

ClinicalTrials ID:NCT04623801

Patient View

This study evaluates the safety and efficacy of percutaneous laser ablation (PLA) for papillary thyroid microcarcinoma. Eligible participants are adults with specific cytological and ultrasonographic criteria, a maximum lesion diameter of 13 mm, and no evidence of metastasis. PLA involves a single session using a 21-gauge needle under ultrasound guidance.

Patient Parameters

Program Overview

The purpose of this study is to explore whether percutaneous laser ablation (PLA) is a safe and effective alternative to removing papillary thyroid microcarcinoma (PTMC) with surgery.

Eligibility Criteria

Inclusion Criteria

  • Age ≥ 18 years

  • Papillary thyroid cancer documented by

    • (a) Bethesda VI cytology,
    • (b) Bethesda III, IV, V, or VI cytology AND BRAF V600E mutation, or
    • (c) Bethesda V cytology AND high risk ultrasonographic features documented by either the ATA high suspicion or TIRADS 5 nodule characteristics

To ensure the majority of cases will be eligible based on criteria (a) or (b), we will enroll ≤ 2 patients based on criteria (c).

  • Maximum diameter ≤ 13 mm
  • Declined active surveillance
  • The thyroid lesion must be primarily solid with ≤ 25% cystic compent
  • No US evidence of extrathyroidal extension through the thyroid capsule
  • No imaging evidence of lymph node metastasis
  • Preserved contralateral vocal cord function prior to PLA

Exclusion Criteria

  • Thyroid cancer that is non papillary thyroid cancer (PTC)
  • Thyroid lesion with > 25% cystic component
  • Lesion with US evidence of extrathyroidal extension through the thyroid capsule
  • Clinical or ultrasonographic evidence of lymph node metastasis
  • Pregnancy

Get This Program In Your Inbox

You can sign up and apply your patients for this program.